Xencor (NASDAQ:XNCR) Sets New 12-Month Low - What's Next?

Xencor, Inc. (NASDAQ:XNCR - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday . The stock traded as low as $12.23 and last traded at $12.61, with a volume of 61223 shares. The stock had previously closed at $12.95.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. StockNews.com lowered Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Finally, Wells Fargo & Company reduced their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating for the company in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.38.

Xencor Stock Performance

The company has a fifty day moving average of $15.56 and a two-hundred day moving average of $20.08. The stock has a market capitalization of $791.29 million, a P/E ratio of -3.51 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23.

Remove Ads

Xencor (NASDAQ:XNCR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. On average, equities analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Sterling Capital Management LLC grew its position in shares of Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Xencor during the fourth quarter valued at approximately $34,000. GAMMA Investing LLC grew its holdings in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock valued at $49,000 after purchasing an additional 508 shares during the last quarter. Quarry LP raised its position in shares of Xencor by 111.4% during the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock worth $80,000 after purchasing an additional 2,108 shares during the period. Finally, KBC Group NV lifted its holdings in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 813 shares during the last quarter.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.